ADVB

Advanced Biomed Inc. (NASDAQ:ADVB) is a Taiwan-based medical technology company founded in 2014 that specializes in developing microfluidic biochip technologies for cancer detection and diagnosis. The company went public in March 2025 and is headquartered in New York, New York, operating as an investment holding company focused on precision oncology applications. Advanced Biomed represents an emerging player in the liquid biopsy market, developing sophisticated laboratory devices and diagnostic kits designed to detect circulating tumor cells in blood samples, which could potentially revolutionize early cancer screening and monitoring.